A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria * For All Participants * Have received at least one standard therapy unless it does not exist, or available therapies are intolerable or no longer effective. * For participants, who qualify for approved molecularly selected therapies such as RAS inhibitors, they must have progressed on, relapsed from, been intolerant to, ineligible, or refused those therapies. * Expansion Stage * Diagnosis of metastatic advanced UC (primary tumor: renal pelvis, ureter, urinary bladder, or urethra). * At least one measurable lesion as defined by RECIST, version 1.1. * Participants must be eligible for sacituzumab govitecan treatment as their next line of therapy. * At least one but no more than 3 prior lines of therapy. * Eastern Cooperative Oncology Group (ECOG) Performance Status (0-2 for monotherapy; 0-1 for combo) Exclusion Criteria * Prior anticancer treatment, including: * Radiation therapy within 2 weeks before first dose of study treatment. * Known brain metastases or cranial epidural disease * Current or recent severe illness * Known history or positive test for human immunodeficiency virus (HIV) unless meets specific criteria. * Active infection with hepatitis B virus or hepatitis C virus. * Malabsorption syndrome. * History of solid organ, autologous or allogenic stem cell transplant. * Diagnosis of another cancer within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured …